Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
10.1016/j.jbc.2022.102279 20 DaleN
Watanabe T, Tanigawa T, Nadatani Y, et al
"By definition, anything featured is well-known and at risk of mean reversion after massive outperformance." Shares of Novo Nordisk and Eli Lilly have seen massive outperformance over the past few years as investors sized up the $100 billion potential of GLP-1 weight loss drugs
Research Compound Profile GLP-1-S GLP-1-S is a synthetic peptide studied for its involvement in glucagon-like peptide-1 (GLP-1) receptor signaling and metabolic regulation pathways
US$ 20.74
US$ 28.68
US$ 21.36
US$ 26.15
US$ 24.50
US$ 24.68
